Bromide as marker for drug adherence in hypertensive patients

被引:10
作者
Braam, Richard L. [1 ]
van Uum, Stan H. M. [2 ,3 ]
Lenders, Jacques W. M. [1 ]
Thien, Theo [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands
[2] Univ Western Ontario, Dept Med, London, ON, Canada
[3] Univ Western Ontario, Lawson Hlth Res Inst, London, ON, Canada
关键词
bromide; drug adherence; hypertension;
D O I
10.1111/j.1365-2125.2007.03068.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AIMS Adherence to antihypertensive medication is essential for adequate long-term control of blood pressure (BP). This study investigated different methods of measuring adherence in hypertensive patients. METHODS Patients were included if BP was insufficiently controlled on monotherapy. After a placebo period patients were treated with trandolapril 2 mg/verapamil SR 180 mg (TV). BP was determined using a mercury sphygmomanometer and ambulatory BP monitoring. Adherence was measured by capsule counting, electronic registration of pill-box openings and by measuring serum bromide concentrations. Potassium bromide was added to each TV capsule. RESULTS Thirty patients participated in the study. Treatment with TV significantly lowered office BP and ambulatory BP. Results for electronic monitoring and adherence based on bromide measurements were comparable. Adherence was slightly higher when assessed by capsule counting. CONCLUSIONS Measuring serum bromide concentrations may be suitable for assessment of adherence to drug therapy giving comparable results to electronic monitoring. Using capsule counting, electronic monitoring and measurement of bromide concentrations, nonadherent patients were identified.
引用
收藏
页码:733 / 736
页数:4
相关论文
共 12 条
[1]   Therapy resistant hypertension -: significance of electronic compliance monitoring [J].
Baulmann, J ;
Düsing, R ;
Vetter, H ;
Mengden, T .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (45) :2379-2382
[2]   Bromide as a marker to measure adherence to drug therapy [J].
Braam, RL ;
van Uum, SHM ;
Russel, FGM ;
Swinkels, DW ;
Thien, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (04) :285-290
[3]   Monitoring compliance in resistant hypertension: an important step in patient management [J].
Burnier, M ;
Santschi, V ;
Favrat, B ;
Brunner, HR .
JOURNAL OF HYPERTENSION, 2003, 21 :S37-S42
[4]   LOW-DOSE PHENOBARBITONE AS AN INDICATOR OF COMPLIANCE WITH DRUG-THERAPY [J].
FEELY, M ;
COOKE, J ;
PRICE, D ;
SINGLETON, S ;
MEHTA, A ;
BRADFORD, L ;
CALVERT, R .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (01) :77-83
[5]  
Kim M T, 2000, Prog Cardiovasc Nurs, V15, P90, DOI 10.1111/j.1751-7117.2000.tb00211.x
[6]   MINIMAL DOSES OF DIGOXIN - A NEW MARKER FOR COMPLIANCE TO MEDICATION [J].
MAENPAA, H ;
JAVELA, K ;
PIKKARAINEN, J ;
MALKONEN, M ;
HEINONEN, OP ;
MANNINEN, V .
EUROPEAN HEART JOURNAL, 1987, 8 :31-37
[7]   CONCURRENT AND PREDICTIVE-VALIDITY OF A SELF-REPORTED MEASURE OF MEDICATION ADHERENCE [J].
MORISKY, DE ;
GREEN, LW ;
LEVINE, DM .
MEDICAL CARE, 1986, 24 (01) :67-74
[8]   Drug therapy - Adherence to medication [J].
Osterberg, L ;
Blaschke, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (05) :487-497
[9]   TIME TO STOP COUNTING THE TABLETS [J].
PULLAR, T ;
KUMAR, S ;
TINDALL, H ;
FEELY, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (02) :163-168
[10]  
ROTH HP, 1970, CLIN PHARMACOL THER, V11, P228